Lv1
40 积分 2024-09-25 加入
Combinatorial therapy is a safe and durable treatment option in ALK-rearranged non-small cell lung cancer with an acquired MET exon 14 skipping mutation mediated resistance to alectinib: a case report
1天前
待确认
Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401
3个月前
已完结
Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401
3个月前
已完结
Association of PD-L1 expression with efficacy of alectinib in advanced NSCLC patients with ALK fusion
3个月前
已完结
Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (ALK) rearrangements and co-existing alterations—a retrospective cohort study
3个月前
已完结
Non-Insulin Antidiabetic Agents and Lung Cancer Risk in Drug-Naive Patients with Type 2 Diabetes Mellitus: A Nationwide Retrospective Cohort Study
4个月前
已关闭
Rheumatoid Arthritis — Common Origins, Divergent Mechanisms
5个月前
已完结
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
5个月前
已完结
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
5个月前
已完结
Sunvozertinib: the next candidate of TKI for NSCLC
5个月前
已完结
皖公网安备34019202002308
